Overview
The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.
Eligibility
Inclusion Criteria:
- 0 years < age < 18 years old, regardless of gender;
- Tumor patients diagnosed by histopathology or bone marrow cytology;
- Patients are treated for the first time;
- ECoG score ≤ 2;
- The expected survival time is more than 8 months;
- Patient's parent or guardian signs informed consent.
Exclusion Criteria:
- Combined with immunodeficiency disease
- Second tumor